{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:51:22Z","timestamp":1792857082547,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"19-20","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Stem Cells and Development"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>This study evaluates the clinical efficacy and safety of intravenous allogeneic mesenchymal stem cell (MSC) therapy as an adjunct to standard immunosuppressive treatment in dogs diagnosed with primary immune-mediated hemolytic anemia (IMHA), particularly in cases with inadequate response to conventional immunosuppressive protocols. A total of 157 client-owned dogs with IMHA received MSC therapy at Safari Veterinary Care Center or collaborating clinics. A core cohort of 43 dogs met strict inclusion criteria: confirmed primary IMHA, no significant comorbidities, and receipt of at least two MSC treatments. A retrospective analysis was performed on medical records of treated dogs. Packed cell volume (PCV) trends were used to assess treatment response, with success defined as sustained improvement to \u226530% PCV following MSC therapy. Safety was assessed by reviewing for adverse reactions postinfusion. In the core cohort, 76% (33\/43) of dogs achieved successful hematological recovery. Across the broader cohort, clinical improvement was also observed, particularly in dogs with poor initial response to standard therapy. No serious adverse events were recorded following MSC infusion. Allogeneic MSC therapy appears to be a well-tolerated and potentially effective adjunctive treatment for canine IMHA, particularly in refractory cases. These findings support further investigation in controlled clinical trials.<\/jats:p>","DOI":"10.1177\/15473287251375491","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:36:42Z","timestamp":1757997402000},"page":"413-418","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous Allogeneic Mesenchymal Stem Cell Therapy for Canine Immune-Mediated Hemolytic Anemia: A Retrospective Clinical Evaluation"],"prefix":"10.1177","volume":"34","author":[{"given":"Steven D.","family":"Garner","sequence":"first","affiliation":[{"name":"Safari Veterinary Care Centers, Safari Stem Cell Inc, League City, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Laughrun","sequence":"additional","affiliation":[{"name":"Safari Veterinary Care Centers, Safari Stem Cell Inc, League City, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"e_1_3_5_2_2","first-page":"217","article-title":"Canine immune-mediated hemolytic anemia: Pathophysiology, clinical signs, and diagnosis","volume":"29","author":"Balch A","year":"2007","unstructured":"Balch A, , Mackin A. Canine immune-mediated hemolytic anemia: Pathophysiology, clinical signs, and diagnosis. Compend Contin Educ Vet, 2007; 29:217\u2013225.","journal-title":"Compend Contin Educ Vet"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/avj.12875"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-165x.2001.tb00261.x"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.15406\/jsrt.2017.02.00057"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12815"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom2010046"},{"key":"e_1_3_5_8_2","article-title":"Complement modulation by MSCs: New insights into autoimmune disease therapy","volume":"2023","author":"Zhang M","year":"2023","unstructured":"Zhang M, , Chen J, , Wang Y. Complement modulation by MSCs: New insights into autoimmune disease therapy. Journal of Immunological Research, 2023; 2023:5592376.","journal-title":"Journal of Immunological Research"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343"},{"key":"e_1_3_5_10_2","article-title":"Immunomodulation by mesenchymal stromal cells and their clinical applications","volume":"3","author":"Cagliani J","year":"2017","unstructured":"Cagliani J, , Grande D, , Molmenti EP, et al. Immunomodulation by mesenchymal stromal cells and their clinical applications. J Stem Cell Regen Biol, 2017; 3:10.15436\/2471\u2013100598.17.022.","journal-title":"J Stem Cell Regen Biol"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-03054-0"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1525380"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2015.10.022"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/vr.163.11.323"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/VMRR.S81869"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-019-2087-2"},{"key":"e_1_3_5_17_2","article-title":"Efficacy of autologous mesenchymal stromal cell treatment for chronic degenerative musculoskeletal conditions in dogs: A retrospective study","volume":"9","author":"Armitage AJ","year":"2022","unstructured":"Armitage AJ, , Miller J, , Sparks TH, et al. Efficacy of autologous mesenchymal stromal cell treatment for chronic degenerative musculoskeletal conditions in dogs: A retrospective study. Front Vet Sci, 2022; 9:1014687.","journal-title":"Front Vet Sci"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0599-0"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-015-0371-3"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-070909-105309"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vas.2022.100264"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.08.003"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.009"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2009.0418"}],"container-title":["Stem Cells and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15473287251375491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15473287251375491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15473287251375491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:13:30Z","timestamp":1777706010000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15473287251375491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/15473287251375491"],"URL":"https:\/\/doi.org\/10.1177\/15473287251375491","relation":{},"ISSN":["1547-3287","1557-8534"],"issn-type":[{"value":"1547-3287","type":"print"},{"value":"1557-8534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}